Glenmark Pharmaceuticals launches biosimilar of popular anti-diabetic drug Liraglutide in India

03 Jan 2024 Evaluate

Glenmark Pharmaceuticals has launched a biosimilar of the popular anti?diabetic drug, Liraglutide, for the first time in India. The drug is being marketed under the brand name Lirafit following the approval from the Drug Controller General of India (DCGI). Priced at around Rs 100 for a standard dose of 1.2 mg (per day), this will lower the cost of therapy by around 70%, and will be available only under prescription.

Liraglutide belongs to the class of glucagon?like peptide 1 receptor agonist (GLP?1 RA) drugs, which increase glucose?dependent insulin secretion and decrease in appropriate glucagon secretion. It has been approved globally for the management of type 2 diabetes mellitus in adult patients in the United States and the European Union.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries. 


Glenmark Pharma Share Price

1465.30 -27.05 (-1.81%)
21-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1777.65
Dr. Reddys Lab 1194.55
Cipla 1465.65
Lupin 2043.30
Zydus Lifesciences 944.25
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.